Lineage Cell Therapeutics
LCTX
127 hedge funds and large institutions have $49.7M invested in Lineage Cell Therapeutics in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 22 reducing their positions, and 16 closing their positions.
13,200% more call options, than puts
Call options by funds: $133K | Put options by funds: $1K
68% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 22
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
1% more funds holding
Funds holding: 126 → 127 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.72% less ownership
Funds ownership: 48.6% → 47.89% (-0.72%)
8% less capital invested
Capital invested by funds: $53.8M → $49.7M (-$4.15M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$4.63M |
| 2 |
Comerica Bank
Dallas,
Texas
|
+$1.29M |
| 3 |
BlackRock
New York
|
+$797K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$466K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$310K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$3.64M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.98M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$519K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$348K |
| 5 |
JP Morgan Chase
New York
|
-$200K |
LCTX Hedge Fund Activity: Q1 2025 in Review
127 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2025, worth a combined $49.7M — down 7.7% from $53.8M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new LCTX positions and 16 closed out — a net gain of 2 holders — while 37 added to existing stakes and 22 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $4.63M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $3.64M sold.
- 127 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2025, up from 126 in Q4 2024.
- Funds reported $49.7M of Lineage Cell Therapeutics stock for Q1 2025, down 7.7% quarter-over-quarter.
- 18 funds opened new Lineage Cell Therapeutics positions in Q1 2025 and 16 closed out, a net change of +2 holders.
- The largest Lineage Cell Therapeutics buyer in Q1 2025 was Broadwood Capital, an estimated $4.63M added.
- The largest Lineage Cell Therapeutics seller in Q1 2025 was Perceptive Advisors, an estimated $3.64M sold.
Based on aggregated 13F filings for Q1 2025.